← Back to Search

Virus Therapy

Treatment arm for Color Blindness (Colourbridge Trial)

Phase 1 & 2
Waitlist Available
Led By Dominik Fischer, Prof.
Research Sponsored by STZ eyetrial
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 14 - day 365
Awards & highlights

Summary

The purpose of this study is to proof the safety and efficacy of a single bilateral subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia.

Eligible Conditions
  • Color Blindness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 14 - day 365
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 14 - day 365 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety (AE). Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Secondary outcome measures
Efficacy measures. Number of Participants With improved Visual Function.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Waiting group ArmExperimental Treatment1 Intervention
Waiting group will serve as comparator group first and will receive the treatment at a later timepoint.
Group II: Treatment armExperimental Treatment1 Intervention
single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points

Find a Location

Who is running the clinical trial?

STZ eyetrialLead Sponsor
4 Previous Clinical Trials
109 Total Patients Enrolled
University Hospital TuebingenOTHER
563 Previous Clinical Trials
335,533 Total Patients Enrolled
Ludwig-Maximilians - University of MunichOTHER
355 Previous Clinical Trials
178,611 Total Patients Enrolled
~3 spots leftby Jun 2027